Accelerating Antiviral Discovery for Emerging Viral Pathogens

32 concepts30 papers

The rapid emergence of viral threats—from the global SARS-CoV-2 pandemic to regional outbreaks of Dengue and tick-borne encephalitis—has exposed a critical gap in our medical arsenal. While vaccines provide a primary line of defense, they often cannot be deployed fast enough to protect already infected individuals or those exposed to rapidly evolving variants. As noted by Deu John M. Cruz et al., the lack of specific antiviral treatments for high-burden diseases like Dengue underscores an urgent need for scalable discovery platforms.

Current research is shifting away from slow, one-off drug development toward accelerated pipelines that combine natural product chemistry, computational modeling, and drug repurposing.

Leveraging Natural Chemical Diversity

Nature remains one of the most fertile grounds for antiviral discovery, offering complex molecules that have evolved to interact with biological systems. Researchers are increasingly looking toward medicinal plants to find scaffolds that can inhibit viral replication or entry. For instance, S. K Bajpai et al. demonstrated that extracts from Nyctanthes arbortristis exhibit potent activity against encephalitis-causing viruses, suggesting that traditional medicine can provide a starting point for modern drug validation.

The intuition behind this approach is that natural compounds often target conserved viral mechanisms. Liting Liu et al. identified acteoside from traditional Chinese medicine as a potent inhibitor of the SARS-CoV-2 main protease (Mpro), an enzyme essential for viral replication. Similarly, Jiyoung Kim et al. isolated novel saponins from Aster koraiensis that block viral membrane fusion, preventing the virus from entering host cells entirely. To manage the vast amount of data generated by these studies, Shahid Ullah et al. and the authors developed the AVPCD database, which consolidates information on antiviral phytochemicals to streamline the transition from plant extract to therapeutic lead.

Computational Acceleration and Predictive Modeling

Traditional high-throughput screening (HTS) is resource-intensive. To speed up the process, researchers are employing in silico methods to predict how molecules will interact with viral targets before they ever enter a lab. Sabeena Mustafa and Lamya Alomair utilized virtual screening to identify plant-derived inhibitors for the SARS-CoV-2 Mpro, while Eleonora Proia et al. developed 3D-QSAR (Quantitative Structure-Activity Relationship) models to predict the efficacy of potential inhibitors with high precision.

The challenge with these models is often the scarcity of data for new viruses. Lei Deng et al. addressed this by using deep transfer learning. Their model, DeepCoVDR, leverages large datasets from cancer research and applies that knowledge to predict drug responses for COVID-19, using graph transformers to capture the complex relationships between drug structures and viral targets. In the context of HIV, Brian D. Williamson et al. introduced SLAPNAP, a tool that uses statistical learning to predict the neutralization potency of antibodies based on viral gene sequences, allowing for more precise selection of therapies in clinical trials.

Repurposing and Host-Directed Strategies

Because developing a new drug from scratch can take over a decade, repurposing existing FDA-approved drugs is a vital strategy for emerging pathogens. This approach works by identifying drugs that either target the virus directly or, more innovatively, target the host cell factors that the virus requires to replicate.

Fei Yu et al. discovered that the histamine receptor H1 (HRH1) acts as an alternative entry point for SARS-CoV-2. This finding suggests that common antihistamines could be repurposed to block viral entry. Similarly, Xintong Yan et al. found that Selective Estrogen Receptor Modulators (SERMs), typically used for osteoporosis or cancer, can inhibit the replication of the deadly Severe Fever with Thrombocytopenia Syndrome Virus (SFTSV).

Host-directed therapy is particularly attractive because it is harder for a virus to evolve resistance against a drug that targets a stable host protein than one that targets a rapidly mutating viral protein. J. J. Patten et al. used network analysis to prioritize these host targets, identifying obatoclax as a candidate that reduces viral load by modulating host pathways.

Overcoming Resistance and Delivery Barriers

For established viruses like influenza, the primary hurdle is drug resistance. Tianyu Niu et al. attempted to solve this by creating hybrid molecules, combining the natural product matrine with amantadine fragments to create agents effective against resistant H3N2 strains. Qinghua Cui et al. further argued that targeting the entry mechanism (specifically the hemagglutinin protein) offers a way to achieve broad-spectrum protection across diverse influenza strains.

Finally, even the most potent antiviral is useless if it cannot be delivered effectively. Yigong Guo et al. explored advanced dehydration techniques like spray-freeze drying to create stable nanoparticles for delivering ACE-2, a decoy receptor for SARS-CoV-2. By improving the stability and bioavailability of these complex biological agents, researchers ensure that the therapeutic pipeline extends all the way from the computer screen to the patient.

History & citationVersion 1 · 2026-10-04

Current · Permanent link

View frozen version 1

Cite this direction

Latest version (a living page):

@misc{lacuna_need_for_novel_antiviral_agents_3bc9c439,
  title = {need for novel antiviral agents},
  author = {{Lacuna}},
  howpublished = {Lacuna research direction},
  year = {2026},
  url = {https://lacuna.tiptreesystems.com/direction/need-for-novel-antiviral-agents/rdr_3bc9c4390c7a46cfb685f1095d334bb9},
  note = {Latest version of a living research direction; cite a version for a fixed text. Accessed 2026-11-19},
}

This exact version (version 1, frozen text):

@misc{lacuna_need_for_novel_antiviral_agents_3bc9c439_v1,
  title = {need for novel antiviral agents},
  author = {{Lacuna}},
  howpublished = {Lacuna research direction},
  year = {2026},
  url = {https://lacuna.tiptreesystems.com/direction/need-for-novel-antiviral-agents/rdr_3bc9c4390c7a46cfb685f1095d334bb9/v/1},
  note = {Version 1, frozen 2026-10-04. Accessed 2026-11-19},
}

See something wrong? Report a mistake